Open AccessClinicopathological features and oncological outcomes of patients with young‐onset rectal cancer
Author(s) -
Zaborowski A. M.,
Murphy B.,
Creavin B.,
Rogers A. C.,
Kennelly R.,
Hanly A.,
Martin S. T.,
O'Connell P. R.,
Sheahan K.,
Winter D. C.
Publication year - 2020
Publication title -
british journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.202
H-Index - 201
eISSN - 1365-2168
pISSN - 0007-1323
DOI - 10.1002/bjs.11526
Subject(s) - medicine , colorectal cancer , incidence (geometry) , stage (stratigraphy) , disease , surgery , cancer , chemoradiotherapy , young adult , chemotherapy , adjuvant therapy , paleontology , physics , optics , biology
Background The incidence of rectal cancer among adults aged less than 50 years is rising. Survival data are limited and conflicting, and the oncological benefit of standard neoadjuvant and adjuvant therapies is unclear. Methods Disease‐specific outcomes of patients diagnosed with rectal cancer undergoing surgical resection with curative intent between 2006 and 2016 were analysed. Results A total of 797 patients with rectal cancer were identified, of whom 685 had surgery with curative intent. Seventy patients were younger than 50 years and 615 were aged 50 years or more. Clinical stage did not differ between the two age groups. Patients aged less than 50 years were more likely to have microsatellite instability (9 versus 1·6 per cent; P = 0·003) and Lynch syndrome (7 versus 0 per cent; P < 0·001). Younger patients were also more likely to receive neoadjuvant chemoradiotherapy (67 versus 53·3 per cent; P = 0·003) and adjuvant chemotherapy (41 versus 24·2 per cent; P = 0·006). Five‐year overall survival was better in those under 50 years old (80 versus 72 per cent; P = 0·013). The 5‐year disease‐free survival rate was 81 per cent in both age groups ( P = 0·711). There were no significant differences in the development of locoregional recurrence or distant metastases. Conclusion Despite accessing more treatment, young patients have disease‐specific outcomes comparable to those of their older counterparts.